We will investigate how the master control gene, Kruppel-like factor 1, orchestrates production of red blood cells. We will use genetic and cell biology approaches to determine exactly how this factor interprets the genome blueprint in a cell specific manner. We will also determine how mutations in KLF1 cause human diseases such as congenital dyserythropoietic anemia and hereditary persistence of fetal haemoglobin. This has implications for reactivation of HbF in adults with sickle cell disease.
Novel Transcription Factor Regulation Of Lymphatic Vascular Angiogenesis In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$831,568.00
Summary
Lymphatic vessels control tissue fluid drainage, inflammatory processes and cancer progression. We have used genetic approaches to discover an unexpected role for a family of factors (transcription factors) that regulate new lymphatic vessel formation. This project will investigate this biological function of these genes in detail in vascular formation. The project aims to generate important knowledge for vascular biology, vascular pathologies, cancer spread and future therapeutics.
Elf5 And The Basis For Antiestrogen Resistant Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,181,326.00
Summary
Resistance to anti estrogen therapies causes half of breast cancer deaths. We have recently discovered (Plos Biol 2012) that the transcription factor Elf5 is intimately involved in this process. This grant will develop our understanding of the transcriptional and genomic events involving Elf5 that lead to antiestrogen resistance and metatstasis, to develop new models of antiestrogen resistance, biomarkers that predict antiestrogen resistance and new therapeutic targets and strategies that preven ....Resistance to anti estrogen therapies causes half of breast cancer deaths. We have recently discovered (Plos Biol 2012) that the transcription factor Elf5 is intimately involved in this process. This grant will develop our understanding of the transcriptional and genomic events involving Elf5 that lead to antiestrogen resistance and metatstasis, to develop new models of antiestrogen resistance, biomarkers that predict antiestrogen resistance and new therapeutic targets and strategies that prevent antiestrogen resistance.Read moreRead less
KLFs are master control genes that regulate the expression of many target genes to determine cell fate and to convert one cell fate to another. Mutations in KLFs cause human diseases. This grant will focus on the founding member of the KLF family, KLF1. We will use genomics techniques and animal models to determine how KLF1 works in normal blood cell production and in disease
Role Of ZEB/NuRD Interactions In Haematopoiesis And Lymphoid Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$810,497.00
Summary
Cancers of the blood arise from (epi)genetic changes that enable blood cells to bypass normal survival and growth checkpoints, leading to accumulation of additional mutations that drive full-scale transformation. This grant aims to understand the role of specific transcription factors (that control disease causing genes to be expressed) and how we can use a novel class of epigenetic drugs together with inhibition of these factors to selectively get rid of cancer causing blood cells in the body.
RZR-alpha In The Control Of Proliferative Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$521,706.00
Summary
Four million Australians have cardiovascular disease accounting for 35% of all deaths. CVD is the most expensive disease burden and a National Health Priority. Smooth muscle cell growth is a cause of CVD. However, the mechanisms controlling SMC hyperplasia are poorly understood. This project will provide key insights on the role of RZR-alpha in the pathogenesis of blood vessel disease, and develop novel gene-targeting approaches for new opportunities to control complications of CVD.
Mapping The TNF Pathway: A Qualitative And Quantative Molecular Analysis Of The Components And Post-translational Modifications Involved In Physiological And Pathological TNFR1 Signalling
Funder
National Health and Medical Research Council
Funding Amount
$636,258.00
Summary
TNF is a master regulator of the inflammation response and dysregulated TNF signalling causes many human diseases. We will use a cutting edge mass spectrometry technique that we have developed to analyse molecules required for TNF signalling. Understanding how the TNF signalling works in all cell types and with different forms of ligands will open up therapeutic opportunities to selectively target TNF signalling in inflammatory diseases, such as Rheumatoid Arthritis and Cancer.
Co-operation Between GATA2 Mutation Or Expression And RAS Signalling In AML
Funder
National Health and Medical Research Council
Funding Amount
$860,601.00
Summary
We have identified a gene GATA2 which, when mutated, can lead to leukaemia (blood cancer). We will collect samples worldwide from families and individuals that carry GATA2 mutations and have developed leukaemia, and will screen for other genetic changes that contribute to leukaemia. We have also identified a novel group of patients who have a low GATA2 activity and who also have mutations in the RAS gene, a known contributor to leukaemia. We will determine how these cooperate to cause leukaemia.
A Genome-wide Analysis Of The Epigenetic Control Of Learning And Memory
Funder
National Health and Medical Research Council
Funding Amount
$547,857.00
Summary
The ability to form and recall memories is a fundamental function of the brain. This ability is affected by neurodegenerative diseases such as Alzheimer's Disease. This project will uncover the regulatory framework that defines the brain cells involved in forming memories, and how these change during Alzheimer's Disease progression.
Defining The Role Of GATA2 In Lymphatic Vascular Development As A Means To Understanding How GATA2 Mutations Predispose To Human Lymphedema.
Funder
National Health and Medical Research Council
Funding Amount
$718,890.00
Summary
We have discovered that mutations in the transcription factor GATA2 result in human primary lymphedema, a debilitating disorder resulting from the failure of lymphatic vessels to return tissue fluid to the bloodstream. The goal of this application is to define the role of GATA2 in lymphatic vessels, in order to understand how GATA2 mutations cause lymphedema. Ultimately, we aim to identify targets to which desperately needed therapeutics for the treatment of lymphedema could be generated.